Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc filed a report detailing an internal transaction by non-executive director Dr Hal Barron. On 2026-02-05, Dr Barron recorded a disposal of notional American Depositary Shares in his GSK Executive Supplemental Savings Plan account, involving 67,601.825 ADSs at $59.1700 per ADS.
GSK plc filed a report detailing an internal transaction by non-executive director Dr Hal Barron. On 2026-02-05, Dr Barron recorded a disposal of notional American Depositary Shares in his GSK Executive Supplemental Savings Plan account, involving 67,601.825 ADSs at $59.1700 per ADS.
GSK plc reported an insider share purchase by its Non-Executive Chair, Sir Jonathan Symonds. He bought 2,500 ordinary shares of 31¼ pence each at a price of £21.1400 per share on 5 February 2026 on the London Stock Exchange. This Form 6-K records the required PDMR (person discharging managerial responsibilities) transaction notification for the company’s ordinary shares.
GSK plc reports that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils despite inhaled triple therapy (ICS, LABA, LAMA).
The approval is based on the phase III MATINEE trial, where mepolizumab reduced the annualised rate of moderate or severe COPD exacerbations versus placebo plus standard of care, with a rate ratio of 0.79 and annualised exacerbation rates of 0.80 versus 1.01. MATINEE also showed a reduction in exacerbations requiring emergency department visits and/or hospitalisation, with a rate ratio of 0.65 and annualised rates of 0.13 versus 0.20.
Nucala is described as the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype, and is now approved in Europe across five indications driven by type 2 inflammation, including COPD, severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
GSK plc filed a Form 6-K reporting two insider share sales on the London Stock Exchange. David Redfern, President of Corporate Development, sold 100,000 ordinary shares at £21.09 per share on 2026-02-05.
On the same date, Neil Falkingham, a person closely associated with Lynn Baxter (President, Europe), sold 2,000 ordinary shares at £20.87 per share. Both transactions involved GSK ordinary shares of 31¼ pence each and were executed on XLON.
GSK reports solid 2025 results with growth led by Specialty Medicines and confirms its medium-term outlook. Turnover reached £32.7 billion, up 7% at constant exchange rates, while Core operating profit rose 11% and Core EPS increased 12% to 172.0p.
Specialty Medicines sales grew 17% at constant exchange rates to £13.5 billion, driven by double‑digit gains in HIV, Respiratory, Immunology & Inflammation, and Oncology, where sales rose 43%. Vaccines delivered 2% growth, with strong ex‑US demand for Shingrix, meningitis vaccines and Arexvy offsetting weaker US shingles and RSV trends.
Free cash flow climbed to £4.0 billion, supporting dividends of 66p per share for 2025, a Q4 dividend of 18p, and a planned 70p dividend for 2026, alongside a £2 billion share buyback of which £1.4 billion is executed. For 2026, GSK guides to turnover growth of 3–5% and Core EPS growth of 7–9% at constant exchange rates and reiterates a 2031 sales outlook of more than £40 billion.
GSK reports solid 2025 results with growth led by Specialty Medicines and confirms its medium-term outlook. Turnover reached £32.7 billion, up 7% at constant exchange rates, while Core operating profit rose 11% and Core EPS increased 12% to 172.0p.
Specialty Medicines sales grew 17% at constant exchange rates to £13.5 billion, driven by double‑digit gains in HIV, Respiratory, Immunology & Inflammation, and Oncology, where sales rose 43%. Vaccines delivered 2% growth, with strong ex‑US demand for Shingrix, meningitis vaccines and Arexvy offsetting weaker US shingles and RSV trends.
Free cash flow climbed to £4.0 billion, supporting dividends of 66p per share for 2025, a Q4 dividend of 18p, and a planned 70p dividend for 2026, alongside a £2 billion share buyback of which £1.4 billion is executed. For 2026, GSK guides to turnover growth of 3–5% and Core EPS growth of 7–9% at constant exchange rates and reiterates a 2031 sales outlook of more than £40 billion.
GSK plc reports its share capital and voting rights position as of 31 January 2026. The company had 4,316,103,805 ordinary shares of 31¼ pence each in issue, with 240,019,489 shares held in treasury. This leaves 4,076,084,316 voting rights currently available to shareholders.
Shareholders can use this voting rights figure as the denominator when calculating whether they must notify new or changed holdings under UK disclosure rules.
GSK plc, through subsidiaries GlaxoSmithKline LLC and Redrose Acquisition Co., has launched an all-cash tender offer to acquire RAPT Therapeutics, Inc.. The offer is for $58.00 per share for each share of RAPT common stock, payable in cash without interest and subject to withholding taxes.
The offer covers all outstanding RAPT common shares and is made pursuant to an Agreement and Plan of Merger dated January 19, 2026. RAPT has advised that 30,922,702 shares of common stock were issued and outstanding as of the close of business on January 28, 2026.
GSK plc, through subsidiaries GlaxoSmithKline LLC and Redrose Acquisition Co., has launched an all-cash tender offer to acquire RAPT Therapeutics, Inc.. The offer is for $58.00 per share for each share of RAPT common stock, payable in cash without interest and subject to withholding taxes.
The offer covers all outstanding RAPT common shares and is made pursuant to an Agreement and Plan of Merger dated January 19, 2026. RAPT has advised that 30,922,702 shares of common stock were issued and outstanding as of the close of business on January 28, 2026.
GSK plc reports that its RSV vaccine Arexvy has been approved by the European Commission for expanded use in adults aged 18 years and older. The vaccine was previously authorised in the European Economic Area for preventing lower respiratory tract disease caused by RSV in adults 60 and over and in adults 50 to 59 at increased risk.
This broader indication means European countries can now make Arexvy available to all adults 18+, potentially addressing a substantial disease burden. In the European Union, an average of 158,000 adults aged 18 and over are hospitalised each year with RSV-related illness. GSK notes that RSV can worsen chronic conditions such as COPD, asthma and chronic heart failure and can lead to pneumonia, hospitalisation and death.
The company highlights that Arexvy combines a recombinant RSV glycoprotein F antigen with GSK’s AS01E adjuvant, and that its use should follow official recommendations since not all vaccinees may develop protective immunity. GSK is also seeking expanded indications for this RSV vaccine in other geographies, including the US and Japan.
GSK plc reports that its RSV vaccine Arexvy has been approved by the European Commission for expanded use in adults aged 18 years and older. The vaccine was previously authorised in the European Economic Area for preventing lower respiratory tract disease caused by RSV in adults 60 and over and in adults 50 to 59 at increased risk.
This broader indication means European countries can now make Arexvy available to all adults 18+, potentially addressing a substantial disease burden. In the European Union, an average of 158,000 adults aged 18 and over are hospitalised each year with RSV-related illness. GSK notes that RSV can worsen chronic conditions such as COPD, asthma and chronic heart failure and can lead to pneumonia, hospitalisation and death.
The company highlights that Arexvy combines a recombinant RSV glycoprotein F antigen with GSK’s AS01E adjuvant, and that its use should follow official recommendations since not all vaccinees may develop protective immunity. GSK is also seeking expanded indications for this RSV vaccine in other geographies, including the US and Japan.
GSK plc, through subsidiaries GlaxoSmithKline LLC and Redrose Acquisition Co., has filed pre-commencement materials for a planned cash tender offer to acquire all issued and outstanding shares of RAPT Therapeutics, Inc. common stock under an Agreement and Plan of Merger dated January 19, 2026.
The tender offer has not yet started. Once it begins, GSK and its affiliates will file a full tender offer statement on Schedule TO, and RAPT will file a Schedule 14D-9 explaining the board’s recommendation. Stockholders are urged in the communication to read these future documents carefully when available, as they will contain detailed terms of the offer, conditions to closing and other important information, alongside extensive forward-looking statement and risk-factor disclosures about the proposed acquisition and related clinical and regulatory expectations.
GSK plc, through subsidiaries GlaxoSmithKline LLC and Redrose Acquisition Co., has filed pre-commencement materials for a planned cash tender offer to acquire all issued and outstanding shares of RAPT Therapeutics, Inc. common stock under an Agreement and Plan of Merger dated January 19, 2026.
The tender offer has not yet started. Once it begins, GSK and its affiliates will file a full tender offer statement on Schedule TO, and RAPT will file a Schedule 14D-9 explaining the board’s recommendation. Stockholders are urged in the communication to read these future documents carefully when available, as they will contain detailed terms of the offer, conditions to closing and other important information, alongside extensive forward-looking statement and risk-factor disclosures about the proposed acquisition and related clinical and regulatory expectations.
RAPT Therapeutics, Inc. is the target of a planned acquisition by GSK plc, which intends to launch a cash tender offer for all issued and outstanding shares of RAPT common stock. The transaction will be carried out through GSK’s subsidiaries GlaxoSmithKline LLC and Redrose Acquisition Co. under an Agreement and Plan of Merger dated January 19, 2026.
The filing is a pre-commencement communication, meaning the tender offer has not yet begun. Once it starts, GSK will file a detailed Schedule TO and RAPT will file a Schedule 14D‑9, providing terms of the offer and the board’s recommendation. The document also includes extensive forward‑looking statement disclosures, highlighting risks such as timing of the offer, satisfaction of closing conditions, required regulatory approvals, potential termination of the merger agreement and possible business disruptions if the deal does not close.
RAPT Therapeutics, Inc. is the target of a planned acquisition by GSK plc, which intends to launch a cash tender offer for all issued and outstanding shares of RAPT common stock. The transaction will be carried out through GSK’s subsidiaries GlaxoSmithKline LLC and Redrose Acquisition Co. under an Agreement and Plan of Merger dated January 19, 2026.
The filing is a pre-commencement communication, meaning the tender offer has not yet begun. Once it starts, GSK will file a detailed Schedule TO and RAPT will file a Schedule 14D‑9, providing terms of the offer and the board’s recommendation. The document also includes extensive forward‑looking statement disclosures, highlighting risks such as timing of the offer, satisfaction of closing conditions, required regulatory approvals, potential termination of the merger agreement and possible business disruptions if the deal does not close.